Search

Your search keyword '"Baldacci, S"' showing total 461 results

Search Constraints

Start Over You searched for: Author "Baldacci, S" Remove constraint Author: "Baldacci, S"
461 results on '"Baldacci, S"'

Search Results

7. Algorithme thérapeutique des cancers bronchiques non à petites cellules étendus avec mutation de l’EGFR

8. Oncogenèse pulmonaire : de l’altération moléculaire au cancer

17. Issue 2 - “Update on adverse respiratory effects of indoor air pollution”. Part 2): Indoor air pollution and respiratory diseases: Perspectives from Italy and some other GARD countries

22. Genetic and environmental influences on infant anthropometry at birth and four months of life: evidence from singleton and twin data in the HEALS and earlyFOOD projects

27. MA07.03 Systematic Engineering of TROP2 CAR T Cell Therapy to Overcome Resistance Pathways in EGFRmutant NSCLC

28. MA07.06 Eradicating Drug Tolerant Persisters (DTPs) In EGFR-Mutated Non Small Cell Lung Cancer (NSCLC) By Targeting TROP2

29. RItA: The Italian severe/uncontrolled asthma registry

30. Exposure to air pollution and allergic diseases in adults

31. Air pollution exposure and prevalence of chronic respiratory diseases in Italy

32. Influence of overweight/obesity, lifestyle and grey space on asthma in Italy

35. Outdoor air pollution and respiratory diseases: A general update and an Italian perspective

40. 1341P NRAS mutated non-small cell lung cancer (NSCLC) patients: Characteristics and outcomes

44. Longitudinal Asthma Patterns in Italian Adult General Population Samples: Host and Environmental Risk Factors

46. Indoor air pollution, physical and comfort parameters related to schoolchildren's health: Data from the European SINPHONIE study

47. Efficacité et tolérance du lorlatinib en 2e ligne ou plus chez les patients, porteurs d’un cancer bronchique non à petites cellules (CBNPC) avancé ROS1+, traités dans le cadre d’une autorisation temporaire d’utilisation (ATU), étude IFCT-1803 LORLATU

48. Efficacité et tolérance du lorlatinib en 2e ligne ou plus chez les patients, porteurs d’un cancer bronchique non à petites cellules (CBNPC) avancé ALK+, traités dans le cadre d’une autorisation temporaire d’utilisation (ATU), étude IFCT-1803 LORLATU

50. 1349P Lorlatinib for advanced ROS1+ non-small cell lung cancer (NSCLC): Efficacy and safety data from IFCT-1803 LORLATU expanded access program (EAP) cohort

Catalog

Books, media, physical & digital resources